Efficacy of SBP-101, in combination with gemcitabine and nab-paclitaxel, in first-line treatment of metastatic pancreatic ductal adenocarcinoma

被引：0
|
作者：
Kotasek, Dusan
Nagrial, Adnan
Lumba, Sumit
Tebbutt, Niall C.
George, Thomas J.
Smith, Sheri Lynn
Gagnon, Suzanne
Cullen, Michael T.
Walker, Michael J.
机构：
[1] Univ Adelaide, Adelaide, SA, Australia
[2] Blacktown Hosp, Canc & Haematol Ctr, Blacktown, NSW, Australia
[3] John Flynn Private Hosp, Canc & Haematol Ctr, Tugun, Qld, Australia
[4] Heidelberg Repatriat Hosp, AfA A A, Olivia Newton John Canc & Wellness Ctr, Heidelberg, Vic, Australia
[5] Univ Florida, Hlth Canc Ctr, Gainesville, FL USA
[6] Courante Oncol, Excelsior, MN USA
[7] Sun BioPharma Inc, Jamestown, RI USA
[8] Sun BioPharma Inc, Waconia, MN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
710
引用
收藏
页数：2
相关论文
共 50 条
  • [31] The efficacy and safety of Nab-paclitaxel plus gemcitabine versus mFOLFIRINOX in the first-line treatment of metastatic pancreatic cancer: a retrospective study
    Lei Yang
    Jing Su
    Wenbo Wang
    Fuxiang Zhou
    World Journal of Surgical Oncology, 21
  • [32] The efficacy and safety of Nab-paclitaxel plus gemcitabine versus mFOLFIRINOX in the first-line treatment of metastatic pancreatic cancer: a retrospective study
    Yang, Lei
    Su, Jing
    Wang, Wenbo
    Zhou, Fuxiang
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2023, 21 (01)
  • [33] Gemcitabine and nab-paclitaxel combination therapy for the treatment of metastatic pancreatic cancer
    Sasaki, Takashi
    Kanata, Ryo
    Saito, Kei
    Yamada, Ikuhiro
    Matsuyama, Masato
    Ozaka, Masato
    Takano, Kouichi
    Sasahira, Naoki
    ANNALS OF ONCOLOGY, 2016, 27
  • [34] Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine as first-line chemotherapy in patients with advanced pancreatic ductal adenocarcinoma: a randomized study
    Zong, Yuan
    Yuan, Jiajia
    Peng, Zhi
    Lu, Ming
    Wang, Xicheng
    Shen, Lin
    Zhou, Jun
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2021, 147 (05) : 1529 - 1536
  • [35] FOLFIRINOX versus gemcitabine plus nab-paclitaxel as the first-line chemotherapy in metastatic pancreatic cancer
    Ay, Seval
    Atci, Muhammed Mustafa
    Arikan, Rukiye
    Dulgar, Ozgecan
    Ozyukseler, Deniz Tataroglu
    Paksoy, Nail
    Dogan, Izzet
    Oztosun, Bugra
    Tastekin, Didem
    Oven, Basak Bala
    Gumus, Mahmut
    JOURNAL OF CHEMOTHERAPY, 2022, 34 (07) : 465 - 471
  • [36] Anlotinib plus nab-paclitaxel/gemcitabine as first-line treatment prolongs survival in patients with unresectable or metastatic pancreatic adenocarcinoma, a retrospective cohort
    Wu, Hongyang
    Huang, Nana
    Zhao, Chenchen
    Hu, Xueyang
    Da, Liangshan
    Huang, Wei
    Shen, Yuanyuan
    Xiong, Fuxing
    Zhang, Congjun
    ANNALS OF TRANSLATIONAL MEDICINE, 2022, 10 (06)
  • [37] Efficacy and tolerance of gemcitabine and nab-paclitaxel in elderly patients with advanced pancreatic ductal adenocarcinoma
    Pignon, Flore
    Turpin, Anthony
    Hentic, Olivia
    Coriat, Romain
    Salmon, Emma
    Baumgaertner, Isabelle
    Bertrand, Nicolas
    Levy, Philippe
    Rebours, Vinciane
    Hammel, Pascal
    de Mestier, Louis
    PANCREATOLOGY, 2021, 21 (06) : 1064 - 1070
  • [38] First-line chemotherapies with FOLFIRINOX or gemcitabine plus nab-paclitaxel for unresectable pancreatic ductal adenocarcinoma in Japanese daily clinical practice
    Yano, M.
    Terashima, T.
    Yamashita, T.
    Miyazawa, M.
    Mizuno, H.
    Nomura, Y.
    Omura, H.
    Takata, Y.
    Ooishi, N.
    Shugo, H.
    Yamada, K.
    Takabatake, H.
    Takatori, H.
    Hodo, Y.
    Nishino, R.
    Hayashi, T.
    Mizukoshi, E.
    Kaneko, S.
    ANNALS OF ONCOLOGY, 2016, 27
  • [39] Nab-paclitaxel plus S-1 followed by gemcitabine-oxaliplatin as first-line alternating sequential treatment of pancreatic ductal adenocarcinoma
    Li, Zhiwei
    Fan, Xiaona
    Jiang, Dan
    Li, Qingwei
    Liu, Chao
    Wang, Dan
    Li, Na
    Li, Hengzhen
    Chen, Zhuo
    Tang, Hongzhen
    Lou, Changjie
    Xu, Haitao
    Zhan, Chao
    Dong, Yuandi
    Ma, Zhigang
    Wang, Guangyu
    Zhang, Chunhui
    Lu, Haibo
    Zheng, Tongsen
    Zhang, Yanqiao
    ONCOLOGIST, 2024, 29 (11):
  • [40] Real-world data comparing FOLFIRINOX versus gemcitabine nab-paclitaxel as first-line treatment of metastatic pancreatic ductal adenocarcinoma patients in the United States.
    Klein-Brill, Avital
    Amar-Farkash, Shlomit
    Lawrence, Gabriella
    Collisson, Eric Andrew
    Fisch, Michael Jordan
    Aran, Dvir
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16271 - E16271
12345